Haemonetics Corporation Common Stock (NY:HAE)

119.79 +1.47 (+1.24%)

Official Closing Price Updated: 4:10 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

3 Reasons to Sell HAE and 1 Stock to Buy Instead

November 17, 2025

Although Haemonetics (currently trading at $74.04 per share) has gained 6.7% over the last six months, it has trailed the S&P 500’s 13% return during that period. This may have investors wondering how...

Via StockStory

Topics Stocks Supply Chain

1 Mooning Stock with Impressive Fundamentals and 2 We Ignore

November 13, 2025

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage...

Via StockStory

Topics Artificial Intelligence

5 Insightful Analyst Questions From Haemonetics’s Q3 Earnings Call

November 13, 2025

Haemonetics’ third quarter results were met with a significant positive market reaction, reflecting both a beat on Wall Street’s revenue and profit expectations and effective execution across its core...

Via StockStory

Topics Earnings

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

9 Analysts Have This To Say About Haemonetics ↗

September 23, 2025

Via Benzinga

SG Capital Dumps Nearly 732,000 Haemonetics Shares Worth $59.1 Million ↗

November 08, 2025

SG Capital Dumps Nearly 732,000 Haemonetics Shares Worth $59.1 Million

Via The Motley Fool

Topics Regulatory Compliance

Why Haemonetics Stock Was on Fire Thursday ↗

November 07, 2025

The hematology specialist delivered a satisfying beat-and-raise fiscal second quarter.

Via The Motley Fool

HAE Q3 Deep Dive: Margin Expansion and Portfolio Rationalization Drive Outperformance

November 07, 2025

Blood products company Haemonetics (NYSE:HAE). announced better-than-expected revenue in Q3 CY2025, but sales fell by 5.3% year on year to $327.3 million. Its non-GAAP profit of $1.27 per share was...

Via StockStory

Why Are Haemonetics (HAE) Shares Soaring Today

November 06, 2025

Shares of blood products company Haemonetics (NYSE:HAE). jumped 22.1% in the morning session after the company reported third-quarter results that surpassed analyst expectations and raised its...

Via StockStory

Topics Artificial Intelligence Economy Government

Datadog, Fastly, Planet Fitness, Air Products And Other Big Stocks Moving Higher On Thursday ↗

November 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 06, 2025

Via Benzinga

Haemonetics (NYSE:HAE) Delivers Impressive Q3, Stock Jumps 12.8%

November 06, 2025

Blood products company Haemonetics (NYSE:HAE). reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell by 5.3% year on year to $327.3 million. Its non-GAAP profit of $1.27 per...

Via StockStory

What To Expect From Haemonetics’s (HAE) Q3 Earnings

November 04, 2025

Blood products company Haemonetics (NYSE:HAE). will be announcing earnings results this Thursday morning. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

3 Russell 2000 Stocks We Think Twice About

October 31, 2025

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these...

Via StockStory

Haemonetics (HAE): Buy, Sell, or Hold Post Q2 Earnings?

October 28, 2025

Over the last six months, Haemonetics’s shares have sunk to $51.21, producing a disappointing 18.2% loss - a stark contrast to the S&P 500’s 24.4% gain. This might have investors contemplating their...

Via StockStory

Topics Stocks Supply Chain

3 Healthcare Stocks We Find Risky

October 24, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of...

Via StockStory

Topics Stocks

Unpacking Q2 Earnings: Haemonetics (NYSE:HAE) In The Context Of Other Medical Devices & Supplies - Specialty Stocks

October 20, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at medical devices & supplies - specialty...

Via StockStory

Medical Devices & Supplies - Specialty Stocks Q2 Results: Benchmarking Haemonetics (NYSE:HAE)

October 19, 2025

Via StockStory

1 Stock Under $50 to Own for Decades and 2 Facing Headwinds

October 15, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

How Do Investors Really Feel About Haemonetics Corp? ↗

October 13, 2025

Via Benzinga

Dentsply Sirona, Acadia Healthcare, and Haemonetics Stocks Trade Down, What You Need To Know

October 10, 2025

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.

Via StockStory

Topics Economy Government World Trade

1 Small-Cap Stock with Competitive Advantages and 2 We Turn Down

October 09, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

3 of Wall Street’s Favorite Stocks Walking a Fine Line

September 29, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Bausch + Lomb, Enovis, and Haemonetics Shares Plummet, What You Need To Know

September 25, 2025

A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential...

Via StockStory

Topics Economy Government World Trade

1 of Wall Street’s Favorite Stock on Our Buy List and 2 We Avoid

September 25, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

What's Driving the Market Sentiment Around Haemonetics? ↗

September 23, 2025

Via Benzinga

1 Profitable Stock for Long-Term Investors and 2 That Underwhelm

September 19, 2025

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

3 Out-of-Favor Stocks We Keep Off Our Radar

September 05, 2025

Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.

Via StockStory

Topics Firearms

Sherwin-Williams, Sealed Air, Super Micro, Globus Medical, and Haemonetics Stocks Trade Up, What You Need To Know

August 22, 2025

A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested...

Via StockStory

Topics ETFs Economy

1 Russell 2000 Stock to Research Further and 2 Facing Headwinds

August 22, 2025

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.